162 related articles for article (PubMed ID: 27789848)
41. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
[TBL] [Abstract][Full Text] [Related]
42. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
43. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
Burgos J; Crespo M; Falcó V; Curran A; Navarro J; Imaz A; Domingo P; Podzamczer D; Mateo MG; Villar S; Van den Eynde E; Ribera E; Pahissa A
J Antimicrob Chemother; 2012 Oct; 67(10):2479-86. PubMed ID: 22729925
[TBL] [Abstract][Full Text] [Related]
44. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
Capetti AF; De Socio GV; Cossu MV; Sterrantino G; Cenderello G; Cattelan A; Baldin GM; Soria A; Riccardi N; Niero FP; Celesia BM; Barbarini G; Rusconi S; Rizzardini G
HIV Clin Trials; 2018 Dec; 19(6):242-248. PubMed ID: 30890064
[TBL] [Abstract][Full Text] [Related]
45. Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients.
Rokx C; Schurink CA; Boucher CA; Rijnders BJ
J Antimicrob Chemother; 2016 Jun; 71(6):1632-6. PubMed ID: 26888910
[TBL] [Abstract][Full Text] [Related]
46. Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Antunes F
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):569-576. PubMed ID: 28443391
[TBL] [Abstract][Full Text] [Related]
47. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
[TBL] [Abstract][Full Text] [Related]
48. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
49. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
Leporrier J; Etienne M; Chapuzet C; Peytavin G; Bord S; Borsa-Lebas F; Caron F; Plantier JC; Mourez T
J Clin Virol; 2014 Aug; 60(4):428-30. PubMed ID: 24932736
[TBL] [Abstract][Full Text] [Related]
50. Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.
Postorino MC; Prosperi M; Quiros-Roldan E; Maggiolo F; Di Giambenedetto S; Saracino A; Costarelli S; Lorenzotti S; Sighinolfi L; Di Pietro M; Torti C;
Clin Microbiol Infect; 2015 Apr; 21(4):386.e1-9. PubMed ID: 25595708
[TBL] [Abstract][Full Text] [Related]
51. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
52. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.
Ghosn J; Carosi G; Moreno S; Pokrovsky V; Lazzarin A; Pialoux G; Sanz-Moreno J; Balogh A; Vandeloise E; Biguenet S; Leleu G; Delfraissy JF
Antivir Ther; 2010; 15(7):993-1002. PubMed ID: 21041914
[TBL] [Abstract][Full Text] [Related]
53. HIV protease inhibitors: recent clinical trials and recommendations on use.
Fernández-Montero JV; Barreiro P; Soriano V
Expert Opin Pharmacother; 2009 Jul; 10(10):1615-29. PubMed ID: 19527188
[TBL] [Abstract][Full Text] [Related]
54. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
Casado JL; Monsalvo M; Rojo AM; Fontecha M; Rodriguez-Sagrado MA
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):561-570. PubMed ID: 29775399
[TBL] [Abstract][Full Text] [Related]
55. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.
Capetti AF; Astuti N; Cattaneo D; Rizzardini G
Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1183-1192. PubMed ID: 28854832
[TBL] [Abstract][Full Text] [Related]
57. Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
Teófilo E; Rocha-Pereira N; Kuhlmann B; Antela A; Knechten H; Santos J; Jiménez-Expósito MJ;
HIV Clin Trials; 2016 Feb; 17(1):17-28. PubMed ID: 26899539
[TBL] [Abstract][Full Text] [Related]
58. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
59. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
60. Short communication: lamivudine plus a boosted-protease inhibitor as simplification strategy in HIV-infected patients: proof of concept.
Casado JL; de la Calle C; del Palacio M; Perez-Elías MJ; Moreno A; Moreno S
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):588-91. PubMed ID: 23163811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
